Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
about
Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinibBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaManagement of Chronic Lymphocytic Leukemia in the ElderlyTargeted therapies in CLL: mechanisms of resistance and strategies for managementThe potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Richter transformation of CLL.Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitorsUnification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activationIbrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemiaAcalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemia therapy: new targeted therapies on the wayIdelalisib for the treatment of non-Hodgkin lymphoma.Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.New Pharmacotherapies in Chronic Lymphocytic Leukemia.Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trialIbrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.The clinical safety of ibrutinib in chronic lymphocytic leukemia.Colorectal cancer in Taiwan: A case-controlled retrospective analysis of the impact of a case management program on refusal and discontinuation of treatment.Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.Chronic lymphocytic leukemia (CLL)-Then and now.Venetoclax for the treatment of patients with chronic lymphocytic leukemia.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.Prognostic Factors for Chronic Lymphocytic Leukemia.The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).The molecular pathogenesis of chronic lymphocytic leukaemia.Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.From identification of the BTK kinase to effective management of leukemia.
P2860
Q26744277-ED2F7034-BA76-41C0-8CD2-9ADF09D394C9Q26765624-452485FC-1CBC-4964-A9BF-3AB4853D62D3Q26775506-84FE8019-578F-4186-AC8A-FA3594E0E8EEQ26775983-9B5E9B4D-2023-439B-A919-10938C166D6CQ27002528-2E89DC83-E194-4865-BFA9-E9DABF18BF7BQ28075504-23702DFB-6626-4465-946A-B2DD16CAC929Q30243968-C9D9FFC5-4B2A-4799-B30B-B7900E723FFFQ30249283-F677C42C-92DF-4D68-A9C6-914FC2DE3EF2Q30252869-AFB4E5E6-3A64-4071-829F-73FDF59A5AF1Q33440942-65F1218E-9AB1-4E8F-A2B3-FB0BF8CB70BCQ33566747-2A3D6048-BF1A-407D-A2B3-8C192E5A0480Q33587128-E4DAD555-D388-4D08-B98E-E69EB68186BCQ35820367-0E97C3F6-3A51-4B71-8982-1BFFD4E30D12Q36651344-3571002D-7D92-4224-A81B-C17B628DCB38Q36888218-C4982503-BB3C-4706-86B5-EC04CF196C82Q37113544-6B0D8B70-DFC3-4FC7-9310-0E337D01C018Q37114445-D2A85064-CBB1-414D-8658-AEBF93911281Q37427124-D28D7B20-E540-4E3C-9513-A03F6B526485Q37605306-61AC8B37-0729-4680-824C-8B00F9163796Q37609908-D6CBB442-668D-4713-A737-8D99EBC2841FQ37633475-F6BCE80A-1578-4F5F-BFFD-9BC128E542B3Q37688589-BF051500-2826-443E-90A4-48C19A264EB1Q37706530-BDBF33EC-B46A-4489-ABF4-FE5173071D71Q37710733-350622E4-1823-4AF3-8236-FBF3F93B2EA4Q38584629-FA87A471-BDD8-4C87-8177-D7C2D5647740Q38612202-E33E2933-CBF3-4B71-81AE-898B4D75263FQ38635212-D831CAE9-69D5-4152-A106-256F544ABEB9Q38646074-820E647B-D04E-40B5-8959-85E8E06FBFBCQ38675358-B6E1437C-A80B-49DF-802C-9A597692D300Q38685358-BBCC1225-A71D-4307-A8C6-D14D45506379Q38691282-DE8771C0-5DD3-49ED-849C-4487031141D6Q38691341-A39CAF65-09CC-41AF-B0EA-0807681B37A3Q38719429-C7893C87-E3C9-4A0F-9AF4-1A1EF0812430Q38729031-5393C8F0-F754-437C-B71E-A1CE1A6BAFEDQ38738661-4D69189D-60CC-45DA-8F63-6219F65DF6E0Q38739050-F7694D5C-351C-4B63-BDAF-A5597DB886DFQ38748645-EE85032F-86F9-4DB0-98A7-849CDE1D43ADQ38765458-5F44F07A-D42D-4AB9-B62D-1186B79F51CCQ38792651-546DA34D-79C3-4AE6-9487-44F1C52A8F27Q38817591-CD87B43D-764C-415F-AC9A-20A0C5569B94
P2860
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Etiology of Ibrutinib Therapy ...... Chronic Lymphocytic Leukemia.
@ast
Etiology of Ibrutinib Therapy ...... Chronic Lymphocytic Leukemia.
@en
type
label
Etiology of Ibrutinib Therapy ...... Chronic Lymphocytic Leukemia.
@ast
Etiology of Ibrutinib Therapy ...... Chronic Lymphocytic Leukemia.
@en
prefLabel
Etiology of Ibrutinib Therapy ...... Chronic Lymphocytic Leukemia.
@ast
Etiology of Ibrutinib Therapy ...... Chronic Lymphocytic Leukemia.
@en
P2093
P2860
P1433
P1476
Etiology of Ibrutinib Therapy ...... Chronic Lymphocytic Leukemia.
@en
P2093
Amber Gordon
Amy J Johnson
Amy S Ruppert
Arletta Lozanski
Farrukh Awan
Gerard Lozanski
Jeffrey A Jones
Jennifer A Woyach
Joseph M Flynn
Kami J Maddocks
P2860
P356
10.1001/JAMAONCOL.2014.218
P577
2015-04-01T00:00:00Z